
|Videos|March 3, 2021
Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Author(s)Urology Times staff
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Advertisement
Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses standard treatment for patients with metastatic urothelial cancer in the frontline setting and beyond.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
5











